Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
Pressrelease: InfiCure Bio secures US patent and publishes new data in a top scientific journal
https://www.mynewsdesk.com/se/umeaa-biotech-incubator/pressreleases/inficure-bio-secures-us-patent-and-publishes-new-data-in-a-top-scientific-journal-3060618?utm_source=rss&utm_medium=rss&utm_campaign=Alert&utm_content=pressrelease
New publication on the liver phenotype of the NIF mouse
Check out our new exciting study describing the liver phenotype of the NIF mouse! We are proud to announce that it has been accepted for publication in Scientific Reports (https://lnkd.in/emhf8h7). In this paper we demonstrate [...]
InfiCure Bio will attend the annual NASH Summit in mid December
InfiCure Bio AB will attend the 4th NASH Summit (https://nash-summit.com) in mid December and our CEO Sofia Mayans will give a talk on our unique NIF mouse on December 16th at 2.45pm EST. Do not [...]
InfiCure Bio attends AFDD November 16-18
Sofia Mayans and Dan Holmberg will attend the Annual AFDD meeting, this year an entirely digital event: https://afdd-summit.com/